Literature DB >> 16525896

Anti-topoisomerase I antibodies in systemic lupus erythematosus as a marker of severe nephritis.

Mohamed A Hamidou1, Marie A Audrain, Agathe Masseau, Christian Agard, Anne Moreau.   

Abstract

The authors report nine patients with systemic lupus erythematosus associated with anti-topoisomerase I antibodies (ELISA test) without features of systemic sclerosis. These antibodies were correlated with the disease activity and might be a marker of the severity of the closely related to difusse proliferative glomerulonephritis.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16525896     DOI： 10.1007/s10067-005-0061-9

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


  7 in total

1.  Avascular necrosis of bone in systemic lupus erythematosus. The predictive role of precipitating autoantibodies.

Authors:  T Watanabe; T Tsuchida; N Kanda; K Tamaki
Journal:  Scand J Rheumatol       Date:  1997       Impact factor: 3.641

2.  Anti-topoisomerase I (anti-Scl-70) antibodies in patients with systemic lupus erythematosus.

Authors:  H A Gussin; G P Ignat; J Varga; M Teodorescu
Journal:  Arthritis Rheum       Date:  2001-02

3.  Association of damage with autoantibody profile, age, race, sex and disease duration in systemic lupus erythematosus.

Authors:  C-S Yee; H Hussein; J Skan; S Bowman; D Situnayake; C Gordon
Journal:  Rheumatology (Oxford)       Date:  2003-02       Impact factor: 7.580

4.  Antitopoisomerase I antibody in patients with systemic lupus erythematosus/sicca syndrome without a concomitant scleroderma: two case reports.

Authors:  H M Al Attia; M S D'Souza
Journal:  Clin Rheumatol       Date:  2003-02       Impact factor: 2.980

5.  Information on diagnosis and management of systemic lupus erythematosus derived from the routine measurement of 8 nuclear autoantibodies.

Authors:  Gheorghe Paul Ignat; Anne-Christine Rat; Jerry J Sychra; Jacqueline Vo; John Varga; Marius Teodorescu
Journal:  J Rheumatol       Date:  2003-08       Impact factor: 4.666

6.  3 cases of anti-Scl-70 (topoisomerase I) antibody associated with central nervous system lupus without renal disorder.

Authors:  M Mukai; A Sagawa; T Atsumi; S Jodo; Y Amasaki; T Nakabayashi; I Watanabe; A Fujisaku; S Nakagawa
Journal:  J Rheumatol       Date:  1993-09       Impact factor: 4.666

7.  Autoantibodies to topoisomerase I in a patient with systemic lupus erythematosus without features of scleroderma.

Authors:  L Stojanov; M Satoh; M A Dooley; M Kuwana; J C Jennette; W H Reeves
Journal:  Lupus       Date:  1995-08       Impact factor: 2.911
  7 in total
  3 in total

1.  Frequent coexistence of anti-topoisomerase I and anti-U1RNP autoantibodies in African American patients associated with mild skin involvement: a retrospective clinical study.

Authors:  Minoru Satoh; Malgorzata E Krzyszczak; Yi Li; Angela Ceribelli; Steven J Ross; Edward K L Chan; Mark S Segal; Michael R Bubb; Eric S Sobel; Westley H Reeves
Journal:  Arthritis Res Ther       Date:  2011-05-10       Impact factor: 5.156

2.  Gender and ethnicity differences in the prevalence of scleroderma-related autoantibodies.

Authors:  Malgorzata E Krzyszczak; Yi Li; Steven J Ross; Angela Ceribelli; Edward K L Chan; Michael R Bubb; Eric S Sobel; Westley H Reeves; Minoru Satoh
Journal:  Clin Rheumatol       Date:  2011-04-27       Impact factor: 2.980

3.  P-Selectin preserves immune tolerance in mice and is reduced in human cutaneous lupus.

Authors:  Rafael González-Tajuelo; Javier Silván; Alicia Pérez-Frías; María de la Fuente-Fernández; Reyes Tejedor; Marina Espartero-Santos; Esther Vicente-Rabaneda; Ángeles Juarranz; Cecilia Muñoz-Calleja; Santos Castañeda; Carlos Gamallo; Ana Urzainqui
Journal:  Sci Rep       Date:  2017-02-02       Impact factor: 4.379
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.